Results 41 to 50 of about 25,610 (245)

Prognostic Impact of Urokinase Plasminogen Activator Receptor Expression in Pancreatic Cancer: Malignant Versus Stromal Cells

Biomarker Insights, 2017
The urokinase plasminogen activator receptor (uPAR) has been proposed as a potential prognostic factor for various malignancies. The aim of this study is to assess the prognostic value of uPAR expression in neoplastic and stromal cells of patients with ...
Susanna WL de Geus, Victor M Baart, Martin C Boonstra, Peter JK Kuppen, Hendrica AJM Prevoo, Andrew P Mazar, Bert A Bonsing, Hans Morreau, Cornelis JH van de Velde, Alexander L Vahrmeijer, Cornelis FM Sier   +10 more
doaj   +1 more source

Prognostic effects of SuPAR and Neopterin Levels on Patients with Lung Cancer

Pteridines, 2020
Background: Two unique biomarkers, soluble form of the urokinase-type plasminogen activator receptor (suPAR) and neopterin, play a crucial role in inflammatory processes.
Yalcin Selim, Demir Mehmet Emin, Ozturk Reyhan, Kılınç Aytün Şadan, Suer Hatice, Karahan Irfan   +5 more
doaj   +1 more source

New Pieces in the Puzzle of uPAR Role in Cell Migration Mechanisms

Cells, 2020
The urokinase (uPA) receptor (uPAR) plays a key role in cell migration. We previously showed that uPAR-negative HEK-293 cells efficiently migrate toward serum but, after uPAR ectopic expression, migrate only in a uPAR-dependent manner. In fact, migration
Anna Gorrasi, Anna Maria Petrone, Anna Li Santi, Mariaevelina Alfieri, Nunzia Montuori, Pia Ragno   +5 more
doaj   +1 more source

Eleven genomic loci affect plasma levels of chronic inflammation marker soluble urokinase-type plasminogen activator receptor

Communications Biology, 2021
Dowsett and colleagues used a genome-wide association approach to investigate the genetic influence on soluble urokinase-type plasminogen activator receptor presence in the plasma of humans.
Joseph Dowsett, Egil Ferkingstad, Line Jee Hartmann Rasmussen, Lise Wegner Thørner, Magnús K. Magnússon, Karen Sugden, Gudmar Thorleifsson, Mike Frigge, Kristoffer Sølvsten Burgdorf, Sisse Rye Ostrowski, Erik Sørensen, Christian Erikstrup, Ole Birger Pedersen, Thomas Folkmann Hansen, Karina Banasik, Søren Brunak, DBDS Genomic Consortium, Vinicius Tragante, Sigrun Helga Lund, Lilja Stefansdottir, Bjarni Gunnarson, Richie Poulton, Louise Arseneault, Avshalom Caspi, Terrie E. Moffitt, Daníel Gudbjartsson, Jesper Eugen-Olsen, Hreinn Stefánsson, Kári Stefánsson, Henrik Ullum   +29 more
doaj   +1 more source

Soluble urokinase plasminogen activation receptor - An emerging new biomarker of cardiovascular disease and critical illness

Annals of Cardiac Anaesthesia, 2016
Soluble urokinase plasminogen activation receptor (suPAR) is an emerging new biomarker, which has been shown to not only correlate with traditional biomarkers but also outperform CRP at prognosticating CVD.
Nicole B Cyrille, Pedro A Villablanca, Harish Ramakrishna   +2 more
doaj   +1 more source

Soluble urokinase plasminogen activator receptor and cardiotoxicity in doxorubicin-treated breast cancer patients: a prospective exploratory study

Cardio-Oncology
Background Soluble urokinase plasminogen activator receptor is an inflammatory biomarker that may prognosticate cardiovascular outcomes. We sought to determine the associations between soluble urokinase plasminogen activator receptor and established ...
Jian Chu, Lillian Tung, Issam Atallah, Changli Wei, Melody Cobleigh, Ruta Rao, Steven B. Feinstein, Lydia Usha, Kathrin Banach, Jochen Reiser, Tochukwu M. Okwuosa   +10 more
doaj   +1 more source

Suppression of osteosarcoma cell invasion by chemotherapy is mediated by urokinase plasminogen activator activity via up-regulation of EGR1. [PDF]

PLoS ONE, 2011
BACKGROUND: The cellular and molecular mechanisms of tumour response following chemotherapy are largely unknown. We found that low dose anti-tumour agents up-regulate early growth response 1 (EGR1) expression. EGR1 is a member of the immediate-early gene
Yukihiro Matsunoshita, Kosei Ijiri, Yasuhiro Ishidou, Satoshi Nagano, Takuya Yamamoto, Hiroko Nagao, Setsuro Komiya, Takao Setoguchi   +7 more
doaj   +1 more source

Thrombolytic proteins profiling: High‐throughput activity, selectivity, and resistance assays

FEBS Open Bio, EarlyView.
We present optimized biochemical protocols for evaluating thrombolytic proteins, enabling rapid and robust screening of enzymatic activity, inhibition resistance, and fibrin affinity, stimulation, and selectivity. The outcome translates to key clinical indicators such as biological half‐life and bleeding risk. These assays streamline the development of
Martin Toul, Alan Strunga, Jiri Damborsky, Zbynek Prokop   +3 more
wiley   +1 more source

PAI‐1 inhibits urokinase‐induced chemotaxis by internalizing the urokinase receptor

FEBS Letters, 2001
PAI‐1 (plasminogen activator inhibitor‐1) binds the urokinase‐type plasminogen activator (uPA) and causes its degradation via its receptor uPAR and low‐density lipoprotein receptor‐related protein (LRP). While both uPA and PAI‐1 are chemoattractants, we find that a preformed uPA–PAI‐1 complex has no chemotactic activity and that PAI‐1 inhibits uPA ...
B. DEGRYSE, C. F. M. SIER, M. RESNATI, F. BLASI, CONESE, MASSIMO   +4 more
openaire   +3 more sources

KLK7 overexpression promotes an aggressive phenotype and facilitates peritoneal dissemination in colorectal cancer cells

FEBS Open Bio, EarlyView.
KLK7, a tissue kallikrein‐related peptidase, is elevated in advanced colorectal cancer and associated with shorter survival. High KLK7 levels in ascites correlate with peritoneal metastasis. In mice, KLK7 overexpression increases metastasis. In vitro, KLK7 enhances cancer cell proliferation, migration, adhesion, and spheroid formation, driving ...
Yosr Z. Haffani, Tobias Dreyer, Meriem Naim, Rea Lo Dico, Natalia A. Ignatenko, Viktor Magdolen, Dalila Darmoul   +6 more
wiley   +1 more source